thank stand welcome labcorp second quarter earn conference call operator instruction operator instruction would like hand conference host today cook vice president investor relation please ahead cook vice president investor operator good morning welcome labcorp second quarter conference call detail today press release replay conference call available telephone internet today chairman chief executive officer executive vice president chief financial officer morning investor relation section website labcorp post press release investor relation presentation additional information business operation include reconciliation financial measure financial measure discuss today call additionally make forward look statement forward look statement include limit statement respect estimate guidance relate assumption include project impact pandemic company business operate result cash flow financial condition response expect future impact pandemic business generally general economic business market condition forward look statement base upon current expectation subject change base upon various factor many beyond control could affect financial result factor forth detail recent annual report form subsequent quarterly report form company file obligation provide update forward look statement even expectation change turn call chairman president chief executive good morning everyone pleasure morning remain commit extensive diagnostics drug development capability advance mission improve health improve life around world innovation technology science remain forefront benefit patient provider shareholder second quarter strong across diagnostics drug development revenue total billion increase period much growth drive continue strength base business adjust reach versus prior year free cash flow million quarter versus million strong performance quarter improve outlook year result raise full year guidance revenue cash flow review guidance moment base business continue recover grow diagnostics drug development respectively drug development trail month book bill remain strong performance drive patient provider return routine healthcare pharmaceutical client resume important research activity even faster pace expect turn company continue response pandemic organization collective strength scale allow play substantial role fight although much progress make clear still work around world labcorp remain vigilant stand ready help wherever however since earliest pandemic date labcorp perform million test quarter steady decline positive case drive overall decrease test average test month lower quarter average however test start increase recent week continue monitor development unite state around world watch delta variant closely support track monitor delta variant quarter announce extension contract provide genetic sequence positive test sample difficult predict exactly test demand look like remainder year variant continue spread enter season therefore maintain ability scale test capacity quickly expand access community individual need time drug development continue involve many study potential vaccine treatment around world automate clinical trial production facility double automate production capacity time allow better serve pharmaceutical client study investigator middle east relate action quarter include collaboration department health human service raise awareness monoclonal antibody therapy state local level expand notable partnership place like north facilitate mass vaccination program expand access home test collection underserved population addition continue collaboration pixel labcorp test available store demand delivery service like importantly scientist data available robust test infrastructure contribute essential research quarter release result largest relate study time analyze test patient offer useful detail body reaction natural infection work learn nature immuno response also build upon portfolio serology test include analysis cell memory remain proud significant contribution extend spread development treatment vaccine intend assist people safely back work normal life activity provide update strategy focus leverage industry lead position drive growth enhance customer patient experience advance science healthcare seek intensify customer focus integrate data digitalization across business part objective announce plan state bioanalytical laboratory expand global drug development offer elevate client experience faster turnaround time unite state continue improve patient experience service center focus effort create seamless digital journey appointment schedule result delivery average three million patient serve give week excite enhance experience digital channel first half year user website total million increase last year adoption patient application grow approximately user month turn oncology make significant stride quarter oncology lead highly train multidisciplinary launch several oncology test include insight cancer tissue base sequence test patient advance solid tumor cancer test specific individual molecular immune profile provide clinical decision support help medical professional identify appropriate treatment option patient identify potential eligibility clinical trial also launch companion diagnostic test identify patient small cell lung cancer eligible treatment option develop important test help physician identify patient benefit treatment promote personalize precision medicine work oncology create meaningful business relationship across healthcare ecosystem continue enhance grow important opportunity present longtime oncology partner pioneer solid tumor profile announce today recently exercise option acquire remain stake company enhance integrate oncology platform expand labcorp extensive oncology diagnostics test portfolio open door patient participation clinical trial continue concentrate identify engage high growth opportunity announce acquire autoimmune business unit myriad genetics include rheumatoid arthritis assay strengthen position predict impact roughly adult unite state additionally agree week acquire outreach laboratory business base north health provide management service inpatient pipeline acquisition investment target robust believe meaningful business development opportunity year enhance growth strategy move forward finally want touch briefly board management ongoing review labcorp structure capital allocation strategy announce march year work closely advisor make progress identify best path forward position labcorp unlock shareholder value continue support patient customer around world though update today look forward share conclusion review complete expect fourth quarter conclusion quarter strong across diagnostics drug development business significant progress achieve strategy mission improve health improve life people around world continue support effort stem however optimistic future growth opportunity continue success want thank colleague around world tireless effort help stem also retain focus strategy underlie business turn call review detail second quarter performance executive vice president chief financial start comment review second quarter result follow discussion performance segment conclude update full year guidance revenue quarter billion increase last year organic growth acquisition favorable foreign currency translation basis point organic base business increase compare base business last year test revenue million flat last year operate income quarter million revenue quarter million amortization million restructure charge special item exclude item adjust operate income quarter million revenue compare million last year increase adjust operate income margin primarily organic base business growth acquisition save partially offset higher personnel second quarter interest expense million million increase onetime associate company refinance billion senior note mature take advantage historically interest rate environment exclude onetime interest expense would million versus last year lower debt level interest rate rate quarter adjust rate exclude restructure charge special item amortization compare last year higher adjust rate primarily geographic earn continue expect full year adjust rate approximately earn quarter million dilute share adjust exclude amortization restructure charge special item quarter last year operate cash flow million quarter compare million year increase operate cash flow favorable work capital partially offset lower cash earn capital expenditure total million revenue compare million revenue last year result free cash flow million quarter compare million last year quarter million cash flow share repurchase program review segment performance begin diagnostics revenue quarter billion increase compare last year organic growth acquisition favorable foreign exchange translation basis point organic base business growth compare base business last year test revenue flat versus last year relative second quarter compound annual growth rate base business revenue primarily organic growth total volume increase last year primarily organic volume growth increase organic volume increase base business partially offset reduction test reminder include hospital management agreement volume would approximately organic base business volume growth price increase last year currency test acquisition partially offset organic base business minus associate volume recovery diagnostics organic base business revenue growth compare base business last year drive volume price increase test accession diagnostics adjust operate income quarter million revenue compare million last year increase adjust operate income margin primarily organic base business demand save partially offset higher personnel relative second quarter base business margin slightly negative impact diagnostics margin second quarter year compare first quarter lower test base business margin increase diagnostics three year initiative remain track deliver approximately million save year review performance drug development revenue quarter billion increase compare last year organic growth acquisition favorable foreign currency translation basis point drug development deliver broad base revenue growth across business include vaccine therapeutic study relative second quarter compound annual growth rate base business revenue approximately primarily drive organic growth adjust operate income segment million revenue compare million last year increase adjust operate income margin primarily organic base business demand save partially offset higher personnel relative second quarter base business margin approximately basis point second quarter margin year lower first quarter expect second half base business margin versus first half also expect full year margin year trail month order book bill remain strong billion respectively backlog quarter billion increase approximately million last quarter expect approximately billion backlog convert revenue next month full year guidance assume foreign exchange rate effective full year raise full year guidance reflect company strong second quarter performance improve outlook remainder year diagnostics drug development base business expect enterprise level revenue grow prior guidance include benefit foreign currency translation basis point guidance range also include expectation base business grow test expect raise expectation revenue diagnostics minus plus prior guidance minus flat guidance range include expectation base business grow test revenue expect also raise growth expectation revenue drug development prior guidance current guidance include benefit foreign currency translation basis point guidance range also include expectation base business grow give improve line growth expectation base business raise adjust guidance prior guidance free cash flow expect billion billion prior guidance billion billion earn guidance assume free cash flow acquisition share repurchase expect accelerate second half year expect capital expenditure approximately revenue drive investment support base business growth productivity additional comparison purpose also include supplemental deck investor relation website view second quarter result full year guidance compare result summary company another quarter strong performance remain focus perform critical role response global pandemic also grow base business progress expect drive continue profitable growth base business test volume expect decline second half expect continue free cash flow generation acquisition supplement organic growth also return capital shareholder share repurchase program operator take question